5802-79-9

Usage

Uses

Used in Pharmaceutical Research:
CNPH is used as a research compound for investigating its potential antibacterial and anticancer properties. Its unique chemical structure allows for the exploration of new drug candidates for various therapeutic applications.
Used in Drug Development:
CNPH is utilized in the development of new pharmaceuticals, particularly in the areas of antibacterial and anticancer treatments. Its properties make it a promising candidate for the creation of novel drugs to combat resistant bacterial strains and cancer cells.
Used in Medicinal Chemistry:
CNPH serves as a valuable tool in medicinal chemistry for studying the interactions between chemical compounds and biological targets. Its structure and properties contribute to the understanding of drug mechanisms and the design of more effective therapeutic agents.

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 100-16-3 4-nitrophenylhydrazone 

Downstream Products

• 107915-32-2 2-(4-chloro-phenyl)-3-(4-nitro-anilino)-thiazolidin-4-one 
• 345291-51-2 (4-chloro-α-nitro-benzylidene)-(4-nitro-phenyl)-hydrazine 
• 1090-90-0 α-bromo-(p-chloro-benzaldehyde)p-nitrophenylhydrazone 
• 77721-87-0 (4-Chloro-phenyl)-[(4-nitro-phenyl)-hydrazono]-acetonitrile 
• 77722-09-9 5-(4-Chloro-phenyl)-3-(4-nitro-phenyl)-3H-[1,3,4]thiadiazol-2-one 
• 77721-95-0 5-(4-Chloro-phenyl)-3-(4-nitro-phenyl)-3H-[1,3,4]thiadiazol-2-ylideneamine 
• 77722-05-5 C₁₄H₈ClN₅O₃S 
• 77721-98-3 N-[5-(4-Chloro-phenyl)-3-(4-nitro-phenyl)-3H-[1,3,4]thiadiazol-(2Z)-ylidene]-acetamide 
• 77721-91-6 N-[1-Benzenesulfonyl-1-(4-chloro-phenyl)-meth-(Z)-ylidene]-N'-(4-nitro-phenyl)-hydrazine 
• 77722-14-6 3-(4-Chloro-phenyl)-1-(4-nitro-phenyl)-5-phenyl-1H-pyrazole-4-carbonitrile 
• 77729-01-2 N-[5-(4-Chloro-phenyl)-3-(4-nitro-phenyl)-3H-[1,3,4]thiadiazol-(2Z)-ylidene]-benzamide 
• 61457-33-8 5-amino-3-(4-chloro-phenyl)-1-(4-nitro-phenyl)-1H-pyrazole-4-carboxylic acid anilide 
• 1014625-51-4 3-(4-chloro-phenyl)-1-(4-nitro-phenyl)-5-p-tolyl-1H-pyrazole 
• 85953-62-4 C₁₃H₁₂ClN₅O₂ 

Relevant academic research and scientific papers

Structure-Based Rational Design of Novel Inhibitors Against Fructose-1,6-Bisphosphate Aldolase from Candida albicans

Class II fructose-1,6-bisphosphate aldolases (FBA-II) are attractive new targets for the discovery of drugs to combat invasive fungal infection, because they are absent in animals and higher plants. Although several FBA-II inhibitors have been reported, none of these inhibitors exhibit antifungal effect so far. In this study, several novel inhibitors of FBA-II from C. albicans (Ca-FBA-II) with potent antifungal effects were rationally designed by jointly using a specific protocols of molecular docking-based virtual screening, accurate binding-conformation evaluation strategy, synthesis and enzymatic assays. The enzymatic assays reveal that the compounds 3c, 3e-g, 3j and 3k exhibit high inhibitory activity against Ca-FBA-II (IC50 50 value of 2.7 μM. Importantly, the compounds 3f, 3g, and 3l possess not only high inhibitions against Ca-FBA-II, but also moderate antifungal activities against C. glabrata (MIC80 = 4-64 μg/mL). The compounds 3g, 3l, and 3k in combination with fluconazole (8 μg/mL) displayed significantly synergistic antifungal activities (MIC80 0.0625 μg/mL) against resistant Candida strains, which are resistant to azoles drugs. The probable binding modes between 3g and the active site of Ca-FBA-II have been proposed by using the DOX (docking, ONIOM, and XO) strategy. To our knowledge, no FBA-II inhibitors with antifungal activities against wild type and resistant strains from Candida were reported previously. The positive results suggest that the strategy adopted in this study are a promising method for the discovery of novel drugs against azole-resistant fungal pathogens in the future.